Navigation Links
MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
Date:11/3/2008

GAITHERSBURG, Md., Nov. 3 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most common respiratory infection in infants and can cause disease in otherwise healthy infants and children.

"RSV is a serious respiratory disease that can have significant effects on children. As a leader in pediatric medicine, MedImmune is committed to developing therapies that can combat the most common cause of pediatric respiratory illness," said Filip Dubovsky, M.D., M.P.H, vice president, clinical development, vaccines. "Because respiratory illness due to RSV occurs in otherwise healthy children, developing a vaccine is a public health priority."

MedImmune is a world leader in the development of innovative therapeutic biologic products for prophylaxis and prevention of infectious diseases. This Phase 1/2a clinical trial is designed to assess the safety, tolerability, immunogenicity and viral shedding of the intranasal RSV vaccine in infants and young children. It is a randomized, double-blind, placebo-controlled and multi-dose study that will enroll 320 children.

The investigational vaccine, MEDI-559, is being developed through a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NAID), part of the National Institutes of Health, to help address RSV disease in children. The vaccine was originally developed in the NAID Division of Intramural Research by a team led by Peter L. Collins, Ph.D. and Brian R. Murphy, M.D.

About RSV

RSV is the most important cause of viral lower respiratory tract illness in infants worldwide. Each year, an estimated 125,000 infants in the United States are hospitalized with severe RSV infections. RSV is the most common respiratory infection i
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
4. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
5. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
6. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
7. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
8. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
9. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Talyst, a market leader in pharmacy automation and ... Summer Conference in Las Vegas, NV. ... products and services.   Talyst is the ... customers with a variety of software and services. Talyst ... solution, AutoSplit® Contract Pharmacy and 340B Compliance Services. AutoSplit ...
(Date:8/19/2014)... , Aug. 19, 2014  As power morcellator ... country, Bernstein Liebhard LLP notes that women in ... between a number of options that do not ... instrument. According to a report published by The ... these options include a mini-laparotomy and vaginal hysterectomy. ...
(Date:8/19/2014)... RIDGEFIELD, Conn. , Aug. 19, 2014 /PRNewswire/ ... and Drug Administration (FDA) accepted for review the ... (FDC) of tiotropium and olodaterol delivered via the ... of long-term, once-daily maintenance treatment of airflow obstruction ... including chronic bronchitis and/or emphysema. Tiotropium + olodaterol ...
Breaking Medicine Technology:Talyst Exhibits at the NPPA Summer Conference 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
... , NEW YORK, Dec. 2 Reportlinker.com ... in its catalogue: , Cardiovascular Devices: Technologies ... , Offer a comprehensive view of the cardiovascular devices ... of the major types of cardiovascular diagnostic equipment, including ...
... , ... new market research report is available in its catalogue: ... Trends , http://www.reportlinker.com/p0164212/Chiral-Technology---International-Technology--Market-Trends.html , The ... a flurry of activity with pharmaceutical companies adding chiral ...
Cached Medicine Technology:Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 2Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 3Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 4Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 5Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 6Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 7Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 8Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 9Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 10Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 11Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 12Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5
(Date:8/20/2014)... 20, 2014 “Have you recently been involved ... and personal injury lawyer serving the greater Seattle area. “Are ... so, then keep reading . , In a recently ... in an auto accident can use to see if they ... a personal injury insurance claim will allow an individual to ...
(Date:8/20/2014)... The “Human Insulin Market by Product ... Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], ... Others) - Forecast to 2019” provides a detailed ... market trends,and strategies impacting the global human insulin ... the revenue and share analysis. , Browse 110 ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Mixberry Media ... speech-enable their websites and create a new source of ... consume content by listening to a narration of their ... reader genders and languages. Users can now multitask: ... social networks, while consuming content. , Mixberry ...
(Date:8/20/2014)... August 20, 2014 Over 31 million Americans ... of Disease, low back pain is the single leading cause ... reasons for missed work. Americans spend at least $50 billion ... Most cases of back pain are not due to organic ... , For example, Pete, a busy accountant, had little time ...
(Date:8/19/2014)... in Houston, Texas, is pleased to announce it is now ... with old fillings that need replacing, will benefit from the ... teeth. , From now on any cavities will be repaired ... amalgam free. Even though amalgam fillings have been deemed as ... children over the age of six, they do contain mercury ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... New Rochelle, NY, August 6, 2009The more time college ... to feel jealous toward their romantic partners, leading to ... will further fuel their jealousy, in an escalating cycle ... in CyberPsychology & Behavior , a peer-reviewed journal ...
... Gene signature detects differences in viral, bacterial infections, ... -- A genomic "signature" in blood appears able to ... viruses, such as the cold or flu, even before ... volunteers who were infected with either a live cold ...
... , , , ... Board: PSTX) today announced record quarterly revenues. , , ... Steven H. Kane, Chief Executive Officer of Patient Safety Technologies. ... adopting the Safety Sponge((TM)) System as the solution to the problem ...
... SOUTH PASADENA, Calif., Aug. 6 California Cancer ... center in South Pasadena. The 22,000 s.f. facility, operating under ... in medical, surgical and radiation oncology. In addition, ... San Gabriel Valley to offer RapidArc((TM)), a new and highly ...
... STAMFORD, Conn., Aug. 6 The Purdue Products L.P. ... the National Association of Chain Drug Stores (NACDS) 2009 Marketplace Conference, ... and the primary ingredient is the deseeded pod of the senna ... ) , , "We,ve always ...
... , Report Shows That Making Americans ... , , SAN DIEGO, Aug. 6 As ... decline in public support for health reform efforts, new research shows ... moving the reform needle. , , The ...
Cached Medicine News:Health News:Does Facebook usage contribute to jealousy in relationships? 2Health News:Cold, Flu or Pneumonia? Answer May Lie in Blood Test 2Health News:Patient Safety Technologies Reports Second Quarter Results 2Health News:Patient Safety Technologies Reports Second Quarter Results 3Health News:Patient Safety Technologies Reports Second Quarter Results 4Health News:Patient Safety Technologies Reports Second Quarter Results 5Health News:Patient Safety Technologies Reports Second Quarter Results 6Health News:Patient Safety Technologies Reports Second Quarter Results 7Health News:California Cancer Specialists Medical Group, Inc. Opens Outpatient Cancer Center in South Pasadena, Calif., With Renowned Medical Staff, State-of-the-Art Technology 2Health News:Senokot(R) Tablets Undergo a Natural Makeover 2Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 2Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 3Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 4Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 5Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 6
... provides the most useful measurement for ... states. It is the preferred diagnostic ... patients who have experienced changes in ... dehydration. It is also used to ...
... HemoCue Hemoglobin Test Systems ... reliable quantitative hemoglobin results ... as a large hematology ... consists of either the ...
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
... a qualitative immunoassay for urinary albumin that ... This albumin specific, CLIA Waived test has ... of 95%, and gives accurate results in ... up to 8 hours. Since early detection ...
Medicine Products: